{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:01:29Z","timestamp":1791403289970,"version":"4.3.3"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.abd.2024.10.001","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T12:42:39Z","timestamp":1733316159000},"page":"328-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1561-414X","authenticated-orcid":false,"given":"Paulo","family":"M\u00fcller Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-7757","authenticated-orcid":false,"given":"Alessandra","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-3049","authenticated-orcid":false,"given":"Bruna","family":"Duque-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8807-2556","authenticated-orcid":false,"given":"Daniel Fernandes","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-8535","authenticated-orcid":false,"given":"Flavia","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1052-1777","authenticated-orcid":false,"given":"Leopoldo Duailibe Nogueira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-7102","authenticated-orcid":false,"given":"Lorena Dourado","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-522X","authenticated-orcid":false,"given":"Fabiane","family":"Mulinari-Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2024.10.001_bib0005","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1590\/abd1806-4841.20188802","article-title":"Profile of dermatological consultations in Brazil (2018)","volume":"93","author":"Miot","year":"2018","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0010","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009","volume":"134","author":"Mirzoyev","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0015","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.abd.2020.05.006","article-title":"Consensus on the treatment of alopecia areata - Brazilian Society of Dermatology","volume":"95 Suppl 1","author":"Ramos","year":"2020","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0025","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2024.10.001_bib0030","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2024.10.001_bib0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.23736\/S0392-0488.19.06458-7","article-title":"Italian Guidelines in diagnosis and treatment of alopecia areata","volume":"154","author":"Rossi","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.abd.2024.10.001_bib0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40257-017-0297-6","article-title":"Alopecia areata of the beard: a review of the literature","volume":"18","author":"Cervantes","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0045","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000066435","article-title":"Acute diffuse and total alopecia of the female scalp. A new subtype of diffuse alopecia areata that has a favorable prognosis","volume":"205","author":"Sato-Kawamura","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.abd.2024.10.001_bib0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","article-title":"Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort","volume":"86","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0060","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000254503","article-title":"A new classification of alopecia areata","volume":"131","author":"Ikeda","year":"1965","journal-title":"Dermatologica"},{"key":"10.1016\/j.abd.2024.10.001_bib0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ajd.12941","article-title":"Treatment of alopecia areata: an Australian expert consensus statement","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0070","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/jdv.15994","article-title":"Alopecia totalis and universalis long-term outcomes: a review","volume":"34","author":"Burroway","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2024.10.001_bib0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamadermatol.2023.5869","article-title":"The Alopecia Areata Severity and Morbidity Index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity","volume":"160","author":"Moussa","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.clindermatol.2018.08.011","article-title":"Psychosomatic aspects of alopecia areata","volume":"36","author":"Mulinari-Brenner","year":"2018","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-5945-5-1","article-title":"Concepts of patients with alopecia areata about their disease","volume":"5","author":"Firooz","year":"2005","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0090","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1590\/S0365-05962012000300010","article-title":"Hair loss perception and symptoms of depression in female outpatients attending a general dermatology clinic","volume":"87","author":"Schmitt","year":"2012","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0095","first-page":"6063","article-title":"Severity of depression and anxiety in patients with alopecia areata in Bandar Abbas","volume":"7","author":"Baghestani","year":"2015","journal-title":"Iran. Dermatol Reports"},{"key":"10.1016\/j.abd.2024.10.001_bib0100","article-title":"Psychodermatology: knowledge, awareness, practicing patterns, and attitudes of dermatologists in Turkey","volume":"17","author":"Ocek","year":"2015","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.abd.2024.10.001_bib0105","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/bjd\/ljad253","article-title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials","volume":"189","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0110","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1046\/j.1365-2133.2003.05535.x","article-title":"British Association of D. Guidelines for the management of alopecia areata","volume":"149","author":"MacDonald Hull","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/0974-7753.111223","article-title":"A study to evaluate the efficacy of various topical treatment modalities for alopecia areata","volume":"4","author":"Sardesai","year":"2012","journal-title":"Int J Trichology"},{"key":"10.1016\/j.abd.2024.10.001_bib0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/abd1806-4841.20187423","article-title":"Intralesional betamethasone as a therapeutic option for alopecia areata","volume":"93","author":"Melo","year":"2018","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2016.10.004","article-title":"Alopecia areata: what\u2019s new in epidemiology, pathogenesis, diagnosis, and therapeutic options?","volume":"86","author":"Dainichi","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.abd.2024.10.001_bib0130","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/09546634.2020.1788703","article-title":"Intralesional betamethasone versus triamcinolone acetonide in the treatment of localized alopecia areata: a within-patient randomized controlled trial","volume":"33","author":"de Sousa","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2024.10.001_bib0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/0974-7753.82123","article-title":"Randomized comparison of topical betamethasone valerate foam, intralesional triamcinolone acetonide and tacrolimus ointment in management of localized alopecia areata","volume":"3","author":"Kuldeep","year":"2011","journal-title":"Int J Trichology"},{"key":"10.1016\/j.abd.2024.10.001_bib0140","first-page":"757","article-title":"Alopecia areata: part 2: treatment","volume":"61","author":"Spano","year":"2015","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.abd.2024.10.001_bib0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12788\/j.sder.2015.0160","article-title":"Alopecia areata update","volume":"34","author":"Hordinsky","year":"2015","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.abd.2024.10.001_bib0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1346-8138.2011.01476.x","article-title":"Advances in the management of alopecia areata","volume":"39","author":"Ito","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40257-014-0086-4","article-title":"Alopecia areata: an evidence-based treatment update","volume":"15","author":"Hordinsky","year":"2014","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2015.04.049","article-title":"Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: an intrasubject pilot study","volume":"73","author":"Chu","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0170","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jaad.2019.11.066","article-title":"Efficacy of different concentrations of intralesional triamcinolone acetonide for alopecia areata: a systematic review and meta-analysis","volume":"82","author":"Yee","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0175","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/jocd.13554","article-title":"Use of vibrating anesthetic device reduces the pain of mesotherapy injections: a randomized split-scalp study","volume":"20","author":"Carvalho","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0180","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","article-title":"Alopecia areata update: part II. Treatment","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0185","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1067\/mjd.2003.423","article-title":"Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis\/universalis","volume":"49","author":"Tosti","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0190","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2133.2004.05785.x","article-title":"Minoxidil: mechanisms of action on hair growth","volume":"150","author":"Messenger","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0195","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/187221312800166859","article-title":"Minoxidil use in dermatology, side effects and recent patents","volume":"6","author":"Rossi","year":"2012","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.abd.2024.10.001_bib0200","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.15545","article-title":"Minoxidil for patchy alopecia areata: systematic review and meta-analysis","volume":"33","author":"Freire","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2024.10.001_bib0205","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40272-017-0239-z","article-title":"Alopecia areata: an update on treatment options for children","volume":"19","author":"Peloquin","year":"2017","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.abd.2024.10.001_bib0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","article-title":"Alopecia areata: an appraisal of new treatment approaches and overview of current therapies","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0215","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1087-0024.2003.00812.x","article-title":"Old wine in new bottles: reviving old therapies for alopecia areata using rodent models","volume":"8","author":"Tang","year":"2003","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.abd.2024.10.001_bib0220","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjd.14040","article-title":"Diphenylcyclopropenone in patients with alopecia areata. A critically appraised topic","volume":"173","author":"Kuin","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0225","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/jidsymp.2015.28","article-title":"Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients","volume":"17","author":"Chiang","year":"2015","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.abd.2024.10.001_bib0230","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/pde.13703","article-title":"Treatment of pediatric alopecia areata with anthralin: a retrospective study of 37 patients","volume":"35","author":"Wu","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0235","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11061694","article-title":"Alopecia areata and dexamethasone mini-pulse therapy, a prospective cohort: real world evidence and factors related to successful response","volume":"11","author":"S\u00e1nchez-D\u00edaz","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.abd.2024.10.001_bib0240","first-page":"284","article-title":"Efficacy and safety of oral mega pulse methylprednisolone for severe therapy resistant Alopecia areata","volume":"33","author":"Bin Saif","year":"2012","journal-title":"Saudi Med J"},{"key":"10.1016\/j.abd.2024.10.001_bib0245","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3889\/oamjms.2019.097","article-title":"The effectiveness of oral mini-pulse methylprednisolonein - the treatment of alopecia areata in Vietnam","volume":"7","author":"Thi","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.abd.2024.10.001_bib0250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-4362.1996.tb03281.x","article-title":"Pulsed administration of corticosteroids in the treatment of alopecia areata","volume":"35","author":"Sharma","year":"1996","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0255","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaad.2004.10.873","article-title":"Placebo-controlled oral pulse prednisolone therapy in alopecia areata","volume":"52","author":"Kar","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-016-0111-8","article-title":"Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids","volume":"18","author":"Parente","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.abd.2024.10.001_bib0265","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000092287","article-title":"A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata","volume":"212","author":"Kurosawa","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.abd.2024.10.001_bib0270","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000471771","article-title":"Trichoscopy of steroid-induced atrophy","volume":"3","author":"Pirmez","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.abd.2024.10.001_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.01.062","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0280","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaad.2016.02.1239","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: gastrointestinal and endocrinologic side effects","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0285","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2016.02.1240","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: infectious complications and vaccination recommendations","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0290","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaad.2016.02.1241","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0295","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.abd.2024.10.001_bib0300","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jdv.19665","article-title":"Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2","volume":"38","author":"Senna","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2024.10.001_bib0305","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2217\/imt-2023-0069","article-title":"A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata","volume":"15","author":"King","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.abd.2024.10.001_bib0310","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1372810","article-title":"Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis","volume":"15","author":"Yan","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.abd.2024.10.001_bib0315","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.20351","article-title":"Janus Kinase inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"6","author":"Liu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.abd.2024.10.001_bib0320","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0325","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","article-title":"A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata","volume":"89","author":"Zhou","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0330","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2024.10.001_bib0335","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamadermatol.2023.4090","article-title":"Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis","volume":"160","author":"Ingrassia","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0340","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130078","article-title":"Methotrexate Is a JAK\/STAT pathway inhibitor","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.abd.2024.10.001_bib0350","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000441250","article-title":"Efficacy and safety of methotrexate combined with low- to moderate-dose corticosteroids for severe alopecia areata","volume":"232","author":"Anuset","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.abd.2024.10.001_bib0355","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1590\/abd1806-4841.20142869","article-title":"Efficacy and safety of methotrexate in alopecia areata","volume":"89","author":"Hammerschmidt","year":"2014","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.06.064","article-title":"Methotrexate for alopecia areata: a systematic review and meta-analysis","volume":"80","author":"Phan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0365","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/acr2.11187","article-title":"Adverse effects of low-dose methotrexate in a randomized double-blind placebo-controlled trial: adjudicated hematologic and skin cancer outcomes in the cardiovascular inflammation reduction trial","volume":"2","author":"Vanni","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0370","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.autrev.2014.08.027","article-title":"Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients","volume":"13","author":"Kivity","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.abd.2024.10.001_bib0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2011.00839.x","article-title":"The use of methotrexate in dermatology: a review","volume":"53","author":"Shen","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0380","doi-asserted-by":"crossref","DOI":"10.5070\/D32311037244","article-title":"Does daily folic acid supplementation reduce methotrexate efficacy?","volume":"23","author":"Cline","year":"2017","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.abd.2024.10.001_bib0385","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2019.04.053","article-title":"Cyclosporine for moderate-to-severe alopecia areata: a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety","volume":"81","author":"Lai","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0390","doi-asserted-by":"crossref","first-page":"569","DOI":"10.5021\/ad.2016.28.5.569","article-title":"A comparative study of oral cyclosporine and betamethasone minipulse therapy in the treatment of alopecia areata","volume":"28","author":"Jang","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0395","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1517\/14656566.2012.685160","article-title":"Treatment options for alopecia: an update, looking to the future","volume":"13","author":"Miteva","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.abd.2024.10.001_bib0400","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jaad.2015.12.055","article-title":"Treatment of recalcitrant adult alopecia areata universalis with oral azathioprine","volume":"74","author":"Vano-Galvan","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0405","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1111\/jdv.15834","article-title":"Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata?","volume":"33","author":"Mascia","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2024.10.001_bib0410","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jaad.2024.02.031","article-title":"Role of systemic minoxidil in the treatment of alopecia areata: a scoping review to direct future research","volume":"90","author":"Darchini-Maragheh","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0415","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1001\/archderm.1987.01660350088019","article-title":"Evaluation of oral minoxidil in the treatment of alopecia areata","volume":"123","author":"Fiedler-Weiss","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0420","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaad.2019.08.080","article-title":"Combination tofacitinib and oral minoxidil treatment for severe alopecia areata","volume":"85","author":"Wambier","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0425","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10103-017-2412-6","article-title":"A review of monochromatic light devices for the treatment of alopecia areata","volume":"33","author":"Darwin","year":"2018","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.abd.2024.10.001_bib0430","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/09546634.2019.1687819","article-title":"Meta-analysis of 308-nm excimer laser therapy for alopecia areata","volume":"32","author":"Gupta","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2024.10.001_bib0435","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14764172.2016.1248440","article-title":"A review on laser and light-based therapies for alopecia areata","volume":"19","author":"Mlacker","year":"2017","journal-title":"J Cosmet Laser Ther"},{"key":"10.1016\/j.abd.2024.10.001_bib0440","doi-asserted-by":"crossref","first-page":"505","DOI":"10.5021\/ad.2018.30.4.505","article-title":"Role of hair prostheses (Wigs) in patients with severe alopecia areata","volume":"30","author":"Park","year":"2018","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0445","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/1346-8138.12040","article-title":"Psychosocial impact of wigs or hairpieces on perceived quality of life level in female patients with alopecia areata","volume":"40","author":"Inui","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0450","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","article-title":"Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0455","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/archdermatol.2012.1622","article-title":"The safety and efficacy of diphencyprone for the treatment of alopecia areata in children","volume":"148","author":"Salsberg","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0460","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/12034754241266128","article-title":"Tofacitinib in pediatric alopecia areata totalis and alopecia universalis: a retrospective analysis from India","volume":"28","author":"Gowda","year":"2024","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.abd.2024.10.001_bib0465","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"Torrelo","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0470","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jdv.13896","article-title":"Beard alopecia areata: a multicentre review of 55 patients","volume":"31","author":"Saceda-Corralo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2024.10.001_bib0475","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jaad.2023.05.049","article-title":"Janus kinase inhibitors for alopecia areata","volume":"89","author":"King","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2024.10.001_bib0480","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/13543784.2017.1303480","article-title":"Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia","volume":"26","author":"Barron-Hernandez","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.abd.2024.10.001_bib0485","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0974-7753.77511","article-title":"Bimatoprost in the treatment of eyelash universalis alopecia areata","volume":"2","author":"Vila","year":"2010","journal-title":"Int J Trichology"},{"key":"10.1016\/j.abd.2024.10.001_bib0490","first-page":"419","article-title":"An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects","volume":"10","author":"Borchert","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.abd.2024.10.001_bib0495","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1203475421995186","article-title":"Alopecia areata related paradoxical reactions in patients on dupilumab therapy: a systematic review","volume":"25","author":"Sachdeva","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.abd.2024.10.001_bib0500","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jaad.2017.10.048","article-title":"Objective outcome measures: collecting meaningful data on alopecia areata","volume":"79","author":"Olsen","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624002277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624002277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:52Z","timestamp":1747666852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059624002277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0365059624002277"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2024.10.001","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2024.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}